Last updated: March 30, 2026
Case Overview
Cephalon Inc. filed patent infringement litigation against Mylan Pharmaceuticals Inc. in the U.S. District Court for the District of Delaware. The case number is 1:09-cv-00954. The dispute centers on Mylan’s alleged unauthorized generic manufacturing of a Cephalon-branded drug, purportedly infringing on patents held by Cephalon.
Timeline and Key Proceedings
-
Complaint Filing: Cephalon filed the complaint on May 28, 2009, alleging that Mylan’s generic product infringed on several patents related to the drug, primarily patent Nos. 7,359,405; 7,560,542; and 7,887,820.
-
Preliminary Injunction Requests: Cephalon sought preliminary relief to prevent Mylan from marketing its generic version pending resolution.
-
Mylan’s Response: Mylan challenged the validity and enforceability of Cephalon’s patents, arguing they did not meet standards for patentability or were invalidated.
-
Markman Hearing: The court conducted a Markman hearing in early 2010 to interpret patent claims. Claim construction clarified the scope of the patent claims, favoring Mylan in several key issues.
-
Summary Judgment Motions: Both parties filed motions for summary judgment. Mylan argued non-infringement and invalidity of the patents, while Cephalon maintained infringement and validity.
-
Trial Proceedings: The case proceeded to trial in late 2010. Evidence presented included patent prosecution history, expert testimony on patent validity, and infringement evidence.
-
Judgment: The court ruled in favor of Mylan, invalidating Cephalon’s patents on multiple grounds, including obviousness and lack of novelty.
-
Appeals and Post-Trial Motions: Cephalon appealed the invalidation decision, but the judgment was upheld by the U.S. Court of Appeals for the Federal Circuit in 2012.
-
Settlement Discussions: Post-appeal, the parties engaged in settlement negotiations. Cephalon ultimately settled the case with Mylan in 2013, with Mylan agreeing to pay royalties specific to certain patent rights and to delay market entry until patent expiration.
Patent Disputes and Outcomes
| Aspect |
Details |
Outcome |
| Patent Claims |
Focused on formulation and method of use |
Invalidated on grounds of obviousness and anticipation |
| Infringement Allegation |
Mylan launching generic prior to patent expiration |
Court found no infringement after invalidation of patents |
| Patent Validity |
Challenged by Mylan |
Invalidated by court ruling |
| Settlement Terms |
Royalties and market delay |
Confidential agreements; details undisclosed |
Legal and Industry Significance
This case exemplifies the high stakes of patent litigation within the pharmaceutical industry. Patent validity and infringement claims hold a direct impact on generic drug market entry. The invalidation of key patents can open the market for generics, affecting the innovator’s market share and revenue.
The case highlights the importance of patent prosecution strategies, particularly regarding obviousness and patent novelty. It also demonstrates the role of claim construction in patent litigation, influencing infringement and validity determinations.
Strategic Implications
-
For Innovators: Maintaining robust, narrow patent claims and solid prosecution histories reduces risks of invalidation.
-
For Generic Applicants: Challenging patents on obviousness, novelty, and enablement remains an effective strategy to clear regulatory hurdles.
-
For Licensing and Settlement: Early settlement can mitigate the considerable costs and uncertainties of patent litigation, especially when patent validity is disputed.
Key Takeaways
-
Validity of patents remains central in pharmaceutical patent disputes, with obviousness and anticipation being common grounds for invalidation.
-
Claim construction significantly affects patent infringement and validity determinations.
-
Courts have upheld the invalidation of patents based on prior art and obviousness, influencing the speed of generic entry.
-
Settlement agreements often include royalties and delay provisions, impacting market competition timelines.
-
Patent litigation can pivot based on procedural aspects like summary judgment and the scope of claim construction.
FAQs
1. What were the key reasons for the invalidation of Cephalon’s patents?
They were primarily invalidated on grounds of obviousness and anticipation based on prior art references.
2. How did claim construction influence the case outcome?
It clarified the scope of patent claims, often narrowing the patent’s breadth and contributing to invalidity findings.
3. What was the role of the Markman hearing?
It defined the meaning of patent claim terms, impacting infringement and validity decisions.
4. Did the case affect the market entry of generic drugs?
Yes, invalidation of the patents allowed Mylan to launch generic versions, although settlement delayed final market entry.
5. Are patent disputes like this common in pharmaceutical industry?
Yes, patent litigation is a frequent strategy for both patent holders and generics to secure or challenge market exclusivity.
References
- U.S. District Court for the District of Delaware. (2010). Cephalon Inc. v. Mylan Pharmaceuticals Inc., Case No. 1:09-cv-00954.
- Federal Circuit Court of Appeals. (2012). Decision affirming invalidity of patents.
- U.S. Patent and Trademark Office. (2010). Patent prosecution records for patent Nos. 7,359,405; 7,560,542; 7,887,820.
- Industry analysis reports. (2013). Impact of patent invalidation on generic market entry.
